



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/573,131	04/18/2006	Darrel W. Stafford	5470-401	4529
20792	7590	10/03/2007		
MYERS BIGEL SIBLEY & SAJOVEC			EXAMINER	
PO BOX 37428			SITTON, JEHANNE SOUAYA	
RALEIGH, NC 27627				
			ART UNIT	PAPER NUMBER
			1634	
			MAIL DATE	DELIVERY MODE
			10/03/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

## Interview Summary

**Application No.**

10/573,131

**Applicant(s)**

STAFFORD ET AL.

**Examiner**

Jehanne S. Sitton

**Art Unit**

1634

All participants (applicant, applicant's representative, PTO personnel):

(1) Jehanne S. Sitton.(3) Mary Miller.(2) Ram Shukla.

(4) \_\_\_\_.

Date of Interview: 25 September 2007.

Type: a) ☒ Telephonic b) ☐ Video Conference  
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.  
If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: 1-5.


Identification of prior art discussed: Oldenburg and Rost.

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.



**RAM R. SHUKLA, PH.D.  
SUPERVISORY PATENT EXAMINER**

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

\_\_\_\_\_  
Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: With regard to the rejections under 35 USC 102, Applicant's representative indicated that neither Oldenburg nor Rost teach correlating a polymorphism with "increased sensitivity to warfarin". The examiner inquired as to whether the recitation was defined in the specification. Applicant's representative discussed amending the claims to define the recitation as per the teachings of the specification. With regard to the rejections under 112/first paragraph, enablement and WD, Applicant's representative indicated that the specification taught how to perform additional studies to determine if a particular polymorphism was associated with increased warfarin sensitivity. The examiner indicated that a number of polymorphisms in VKORC1 were found and are taught in the post filing date art, after the instant invention was filed, and that although a population study could be performed, it was unpredictable as to whether any particular polymorphism was correlated to increased warfarin sensitivity. Additionally, the examiner indicated that the single species, that is polymorphism, taught in the specification with regard to increased warfarin sensitivity was not representative of the genus in claims 1 and 3-5 because there was no guidance or description in the specification as to which SNPs are and which are not associated with increased warfarin sensitivity, and that the specification failed to establish a structure/function correlation between the species disclosed and the members of the broadly claimed genus. Applicant's representative indicated that a response would be filed, addressing these arguments.

/Jehanne Sitton/